O
steoporosis is a systemic skeletal disease characterized by low bone mass and microarchitectural deterioration of bone tissue, with a consequent increase in bone fragility and susceptibility to fracture (1) . Approximately 44 million people in the United States are affected by osteoporosis and low bone mass (2) . The clinical complications include fractures, disability, and chronic pain. About 54% of women age 50 years or older will have an osteoporotic fracture during their lifetime (3) . Furthermore, approximately 4% of patients older than 50 years of age who have a hip fracture die while in the hospital and 24% die within 1 year after the hip fracture (4) .
The economic burden of osteoporosis is large and growing. Most estimates are based on the cost of fracture alone: A 1995 estimate of costs incurred by osteoporotic fractures in the United States was $13.8 billion (5) . A 2003 review estimated the total costs in the United States at $17 billion (6) . Although the bulk of these costs were incurred by retired individuals older than age 65 years, direct costs and work loss are significant among employed postmenopausal women (7) . The increasing prevalence and cost of osteoporosis have heightened interest in the efficacy and safety of the many agents available to treat the loss of bone mineral associated with osteoporosis.
This systematic review, developed under the Agency
METHODS
We followed a standardized protocol for the review. The full technical report (8) provides detailed methods, evidence tables, and risk estimates for individual studies. The full report also enumerates studies included in the meta-analyses described in this review.
Data Sources and Study Selection
We searched MEDLINE (1966 to December 2006), the ACP Journal Club database, the Cochrane Central Register of Controlled Trials (no date limits), the Cochrane Database of Systematic Reviews (no date limits), and the Web sites of the National Institute for Health and Clinical Excellence (no date limits) and Health Technology Assessment Programme (January 1998 to December 2006) for materials pertaining to the specified agents, limiting our searches to English-language publications and human studies. We first identified systematic reviews and metaanalyses of trials that reported pooled estimates of the effect of the agents on fracture risk. When such reviews were identified for specific agents, we truncated our searches for randomized trials to include only those published after the last search date used in the review or meta-analysis. We manually searched reference lists of all review articles obtained for any reports of original research not already identified, and we reviewed U.S. Food and Drug Administration (FDA) medical and statistical reviews, scientific information packets from pharmaceutical companies, and additional studies recommended by our technical expert panel and by stakeholders during a public review period. To supplement the information in systematic reviews on estrogen, we reviewed the Women's Health Initiative and Heart and Estrogen/progestin Replacement Study trials, as suggested by our technical expert panel. Finally, we conducted an additional search for large observational studies that reported any of the following adverse events: 1) cardiovascular events (myocardial infarction and stroke); 2) thromboembolic events (pulmonary embolism and venous thromboembolic events); 3) malignant conditions (breast cancer, colon cancer, lung cancer, and osteosarcoma); 4) upper gastrointestinal events (perforations, ulcers, bleeding, and esophageal ulcerations); and 5) osteonecrosis. The search was updated for this paper, but not for the full report, by searching MEDLINE (1 January 2007 to 10 November 2007) for large clinical trials that reported fracture outcomes for the specified agents.
For information on efficacy, we selected meta-analyses that reported pooled risk estimates for fracture and randomized trials that compared any of the agents with placebo or with each other and reported fracture outcomes. For information on harms, we selected systematic reviews, randomized trials, and large case-control or cohort studies with more than 1000 participants. We also reviewed cases of osteonecrosis at AHRQ's request.
Data Extraction and Study Quality
Two physicians independently abstracted data about study populations, interventions, follow-up, and outcome ascertainment by using a structured form. For each group in a randomized trial, a statistician extracted the sample size and number of persons who reported fractures. Two reviewers, under the supervision of the statistician, independently abstracted information about adverse events. Disagreements were resolved by the statistician or the principal investigator. Adverse events were recorded onto a spreadsheet that identified numbers of participants in each trial group and the description of the adverse event as listed in the original article. Each event was counted as if it represented a unique individual. Because an individual may have experienced more than 1 event within a category of adverse events (for example, both stroke and myocardial infarction), this assumption may have overestimated the number of people who had an adverse event in that category. If a trial report mentioned a particular type of adverse event but did not report data on it, we did not include the trial in that particular event's analysis. In other words, we did not assume an occurrence of zero events unless it was specifically reported as such. By taking this approach, we may have overestimated the number of patients for whom a particular adverse event was observed. We used predefined criteria to assess the quality of systematic reviews and randomized trials, based on internal and external validity assessment detailed in the QUOROM (Quality of Reporting of Meta-Analyses) statement (9) , and items related to randomization, blinding, and accounting for withdrawals and dropouts (10, 11) . Each element is detailed in appendices to the full report (8) . For this review, we characterized the overall strength of evidence for estimating fracture risk as good, fair, or weak on the basis of the characteristics previously described, as well as the number
Context
Sorting through the proven benefits and harms of the agents available for treating osteoporosis is difficult.
Contribution
This systematic review of 76 randomized trials and 24 meta-analyses found good evidence that multiple agents, including alendronate, zoledronic acid, and estrogen, prevented vertebral and hip fractures more than placebo. Harms included increased risk for thromboembolic events with raloxifene, estrogen, and estrogen-progestin and increased gastrointestinal symptoms with bisphosphonates. No large trials directly compared 2 or more agents and established superiority of any agent.
Implication
Available data insufficiently characterize the benefits and harms of various therapies for osteoporosis relative to one another.
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Review Preventing Fractures in People with Low Bone Density or Osteoporosis of studies, total number of participants across studies, whether fractures were a primary outcome, reproducibility of results across studies, and precision of the CIs surrounding the point estimates. Evidence was classified as good if the total sample size was greater than 1000, the results across all studies were consistent, and the studies were of high methodological quality. Evidence was classified as fair if results were inconsistent across the studies. The evidence was classified as weak if no studies assessed fracture as a primary outcome, the total sample size across studies was less than 500, and the CIs around the point estimates were wide and crossed null.
Data Synthesis and Statistical Analysis
Comparisons of interest were single agent versus placebo and single agent versus another agent for agents within the same class and across classes. We also compared estrogen-progestin versus placebo or single drugs. Studies that included either calcium or vitamin D in all study groups were classified as comparisons between the other agents in each group; for example, alendronate plus calcium versus risedronate plus calcium would be classified as alendronate versus risedronate.
In this review, we summarize data on vertebral, nonvertebral, and hip fractures; data on total, wrist, and humerus fractures are included in the full report (8) . The number of people with at least 1 fracture was our primary outcome of interest. Because fractures rarely occurred and zero events were often observed in at least 1 treatment group, we calculated odds ratios (ORs) by using the Peto method (12) . Trials with zero events in both groups have an undefined OR. Because fractures are rare events, the OR approximates the relative risk (RR) for fracture. We combined data from multiple study groups in an individual study to calculate a single OR for comparisons of interest. In these instances, the same outcome had been reported for each group, and the individuals in each group were unique. For example, to develop an OR for the risk for vertebral fractures regardless of dose, we combined the participants in the various dose groups and compared them with those in the placebo group. We conducted the metaanalysis by using StatXact PROCs (Cytel, Cambridge, Massachusetts) for SAS software (SAS Institute, Cary, North Carolina).
Recognizing that characteristics of the study population may affect risk for fracture, we defined risk groups to categorize the study populations included in each metaanalysis and randomized, controlled trial on the basis of the risk factors that could be abstracted from these studies ( Table 1) . Based primarily on bone mineral density (13), the expected lifetime risk for fracture in the high-, intermediate-, and low-risk groups would be approximately 33%, 21%, and less than 10% to 21%, respectively. The 10-year risks would range from at least 3% at age 50 years to 10% at age 70 years, at least 1% at age 50 years to 4% at age 70 years, and less than 1% at age 50 years to approximately 2% at age 70 years for the high-, intermediate-, and low-risk groups, respectively.
For the analyses of adverse events, we compared agent versus placebo and agent versus agent for agents within the same class and across classes. We compiled a list of all unique adverse events that were reported in any study, and a physician grouped them into clinically sensible categories and subcategories. For groups of events that occurred in 3 or more trials, we estimated the pooled OR and its associated 95% CI. Because many events were rare, we used exact conditional inference to perform the pooling rather than applying the usual asymptotic methods that assume normality.
Role of the Funding Source
Although AHRQ formulated the initial study questions, it did not participate in the literature search, determination of study eligibility criteria, data analysis, or interpretation. Staff from AHRQ reviewed and provided comments on the report from which this paper is derived.
RESULTS
We identified 2641 titles through various sources (Figure 1) . After reviewing available titles and abstracts, we ordered 1835 articles and could not obtain 10 articles. Intermediate risk ‡ 1) Study entry criteria require T-score ՅϪ1.5 2) 10%-49.99% of population has Ն1 fracture at baseline 3) Study population has chronic disease that is commonly treated with glucocorticoids 4) In the absence of data on BMD or fractures, mean age of population Ն62 years Low risk § 1) Study entry criteria require T-score Յ0.0 2) Ͻ10% of population has BMD of 8 g/cm 2 at baseline 3) Ͻ10% of population has Ն1 fracture at baseline 4) In the absence of data on BMD or fracture, mean age of population Ͻ62 years Unknown risk BMD, fracture history, and age not reported as entry criteria or in baseline characteristics of population Of the 1825 articles screened, we excluded 1721 from efficacy analyses for reasons detailed in Figure 1 . Because comprehensive systematic reviews had recently been conducted for alendronate, risedronate, etidronate, raloxifene, calcitonin, parathyroid hormone (PTH), and estrogen, we did not reanalyze 166 articles on trials of these drugs. We included 76 randomized, controlled trials, 4 of which were identified in the updated search, and 24 meta-analyses in the efficacy analyses. Our analyses of adverse events included 493 articles, representing 417 randomized trials, 25 other controlled clinical trials, 11 open-label trials, 31 large observational studies, and 9 articles reporting cases of osteonecrosis among bisphosphonate users.
Comparative Benefits in Fracture Reduction

Drug versus Placebo Comparisons
For 9 of the 14 agents (alendronate, etidronate, risedronate, calcitonin, estrogen, PTH, raloxifene, calcium, and vitamin D), we identified 24 meta-analyses (14 -38) and 35 additional randomized trials that were published after the meta-analyses (39 -73) and described the effect of the agent compared with placebo on fracture incidence. For 4 of the 5 agents for which we did not identify meta-analyses (ibandronate, pamidronate, zoledronic acid, and tamoxifen), we identified 14 randomized trials (74 -87) that described the effect on the risk for fracture compared with that of placebo. We found no studies that reported fracture rates for testosterone. For calcium plus vitamin D-the only agent combination evaluated for this report-we identified 3 randomized trials that evaluated the risk for fracture compared with that of placebo (39, 88, 89) . We found good evidence from more than 1 randomized trial or meta-analysis that alendronate, etidronate, ibandronate, risedronate, calcitonin, PTH (1-34), and raloxifene, compared with placebo, prevent vertebral fractures. Good evidence from multiple trials and meta-analyses also indicate that both alendronate and risedronate, compared with placebo, prevent nonvertebral and hip fractures. Two large randomized trials showed that zoledronic acid prevents vertebral and nonvertebral fractures in highrisk populations (85, 87) . The risk for hip fracture was reduced in both trials, although the reduction was statistically significant in only 1 trial (85) . A smaller trial was not powered to detect a fracture risk reduction with zoledronic acid (84) . Although 1 large randomized trial detailed in a systematic review showed that PTH (1-34) prevents nonvertebral fractures (90), 2 smaller trials did not (69, 91) .
Good evidence suggests that estrogen by itself is associated with a reduced incidence of vertebral (28, 92), nonvertebral (93) , and hip fractures compared with placebo (92) . Among 3 meta-analyses that assessed the effect of estrogen on the risk for vertebral fracture in postmenopausal women, the pooled sample size in 1 meta-analysis was too small to detect even large differences in fracture risk among groups (22) . Of the remaining 2 meta-analyses, the one with the largest pooled sample size (n ϭ 6723) showed that estrogen reduced fracture risk more than placebo ( A published meta-analysis (24) and several large randomized trials (39, 72, 73, 94) showed no statistically significant difference between calcium alone and placebo in preventing vertebral, nonvertebral, and hip fractures in postmenopausal women. The risk for vertebral fracture for calcium versus placebo among all participants ranged from 0.70 (CI, 0.42 to 1.14) in a trial with 1471 participants (73) 
Within-and Between-Class Comparisons
We identified 9 randomized trials that compared different bisphosphonates (42, 95-102) and 1 randomized trial that compared different selective estrogen receptor modulators (103) . Sixteen randomized trials included head-to-head comparisons of agents from different classes (39 -41, 49 -51, 68, 100, 101, 104 -110). Most were designed to compare changes in intermediate outcomes, such as bone mineral density and changes in markers of bone turnover, but were too small and too short to detect clinically important differences in fracture incidence between groups. We identified only 2 head-to-head trials designed to compare fracture outcomes. One found no difference between risedronate and etidronate for the prevention of vertebral fractures (RR, 0.66 [CI, 0.32 to 1.36]) (95) . The other, which compared raloxifene and alendronate (108), did not recruit enough participants to test differences in fracture outcomes. This study found no difference in the incidence of hip, wrist, or total vertebral fractures, but it was not powered to do so. However, a significant difference in moderate-to-severe vertebral fractures (3 of 713 alendronate recipients with fractures, 0 of 699 raloxifene recipients with fractures; P ϭ 0.04) was found in a prespecified analysis.
Thus, the head-to-head studies had 3 key findings: 1) within the bisphosphonate class, superiority for prevention of fractures has not been shown for any agent; 2) superiority for the prevention of vertebral fractures has not been demonstrated for bisphosphonates compared with calcitonin, calcium, or raloxifene; and 3) on the basis of 6 inadequately powered randomized trials, fracture prevention did not differ between bisphosphonates and estrogen.
Effects in Different Risk Groups
Of the 24 meta-analyses that we reviewed, 6 evaluated the effect of therapy for groups at varying risk for fracture (14, 16, 18, 22, 26, 38) . The criteria used to define risk groups in these studies overlapped but were not identical. In addition, because the risk groups were not always identical to those that we defined for this report, we used expert judgment to match each with one of our risk groups.
Low-Risk Populations
Four meta-analyses (14, 16, 22, 38 ) included a group categorized as low risk according to our criteria, which corresponds approximately to a 10-year risk for fracture of up to 2% and a lifetime risk of up to 21%. Summary estimates from 2 of these analyses suggested possible reductions in the risk for vertebral fracture (RR, 0. (16) , but the width of the 95% CIs suggests that these agents may in fact have had no effect on or increased the risk for fracture.
For estrogen compared with placebo, 1 meta-analysis reported insignificant results with very wide confidence (66) . Two randomized trials in low-risk groups, 1 on the use of calcitonin and 1 on the use of selective estrogen receptor modulators, were completed after publication of the 2 meta-analyses just described. In the first trial, none of 49 calcitonin recipients had fractures at 24 months, compared with 2 of 52 placebo recipients (63). In the second trial, 19 747 postmenopausal women with increased risk for breast cancer (but not selected for fracture risk) were assigned to receive raloxifene or tamoxifen. After 60 months, the proportion of fractures was similar for the 2 groups (104 of 9726 raloxifene recipients with fractures and 96 of (121) .
Among the 6 randomized trials published after the systematic review, 3 found that bisphosphonates reduced fracture rate more than placebo (115) (116) (117) . One trial of risedronate demonstrated a statistically significant reduction in the absolute risk and RR for incident radiographic vertebral fractures (11% and 70%, respectively) after 1 year (117) . The study included data from a trial (121) that was included in the systematic review described in the previous paragraph. Another randomized, controlled trial (116) demonstrated a significant reduction in the risk for incident radiographic vertebral fractures for alendronate compared with placebo (0.7% vs. 6.8%; P Ͻ 0.05). The third trial found a significant (70%) reduction in the incidence of vertebral fractures for risedronate compared with placebo (115) . The remaining 3 trials reported no significant difference in fracture risk between etidronate (50, 52) or calcium (50) and placebo, between calcium and etidronate (50), and between calcium and pamidronate (109) .
A meta-analysis (17) 
Short-and Long-Term Harms (Adverse Effects) of Agents
We assessed adverse events by the system affected. Key findings are summarized in the Appendix Table ( (92) . Risk for osteosarcoma was reported in 1 study, a head-to-head trial of raloxifene versus tamoxifen; differences between the groups were not significant (103).
Osteonecrosis
We found several published cases of osteonecrosis of the jaw in patients with cancer who were taking large doses of bisphosphonates intravenously. Cases involved pamidronate, zoledronic acid, and alendronate. Incidence rates and probability of this adverse event could not be calculated (see the Discussion section).
DISCUSSION
This report summarizes the meta-analyses and subsequent randomized trials that have evaluated the effect of various agents on the risk for osteoporotic fractures. These analyses support a role for many of these agents in reducing the risk for fracture compared with placebo. We did not identify any studies that demonstrated superiority of 1 agent over another in preventing fractures. However, no trial with head-to-head comparisons of 2 or more agents enrolled sufficient sample sizes to detect even large differences in risk.
Consistent with FDA requirements to demonstrate reduced fracture risk to obtain approval of an agent for osteoporosis treatment, many trials were powered to detect a difference in fracture risk among postmenopausal osteoporotic women. These studies provide good evidence that the bisphosphonates alendronate, etidronate, ibandronate, and risedronate, as well as the hormones calcitonin and teriparatide and the selective estrogen receptor modulator raloxifene, prevent vertebral, nonvertebral, or hip fractures in this high-risk group. Each of these agents, with the exception of etidronate, has been approved by the FDA for osteoporosis treatment. Also, consistent with FDA requirements to obtain approval for the prevention of osteoporosis-that is, demonstration of an improvement in bone mineral density, but not necessarily fracture risk reduction, in a population that has not yet shown evidence of osteoporosis-few studies assessed fracture as a primary outcome among these lower-risk individuals. A meta-analysis reported that raloxifene (30) reduces the risk for vertebral fractures in low-risk populations, and 1 trial demonstrated that ibandronate reduces the risk for any fracture in this group (74) . These 2 agents have been approved by the FDA for osteoporosis prevention.
Estrogen is also approved by the FDA for preventing osteoporotic fractures in postmenopausal women. However, the evidence on fracture risk reduction for estrogen is more complex than that for bisphosphonates. The evidence suggests that estrogen reduces the risk for vertebral and hip fracture; however, the effect of estrogen on nonvertebral fracture risk is less clear. Among the 3 meta-analyses that assessed the effect of estrogen on the risk for vertebral fracture in postmenopausal women, only 1 showed an effect that achieved statistical significance (22, 26, 29) . Likewise, the Women's Health Initiative showed that estrogen significantly reduced the risk for hip fracture (67), and a meta-analysis that included data from the Women's Health Initiative showed a reduction in risk for hip fracture that was nonsignificant (22) . Among the 3 meta-analyses that evaluated the risk for nonvertebral fractures, all reported that estrogen reduced risk, but the significance of the results was lower for the 2 meta-analyses with smaller sample sizes (n ϭ 7316 and 5383) (22, 29) . The analysis with the largest sample size (n ϭ 8774) was the only one that showed a significant effect of estrogen (38).
Neither tamoxifen nor testosterone is approved by the FDA for the treatment or prevention of osteoporosis. Consistent with this fact, we did not identify any evidence that these agents reduce the risk for fractures. One large trial provides evidence that tamoxifen is not associated with fracture risk reduction (86) . We did not identify any studies that assessed the effect of testosterone on fracture.
Zoledronic acid is approved by the FDA for the treatment, but not the prevention, of osteoporosis. On the basis of 2 large trials that evaluated the effect of zoledronic acid compared with placebo among postmenopausal women at high risk for fracture, the evidence for a reduced risk for vertebral and nonvertebral fractures is good and that for hip fractures is fair (85, 87) .
The evidence for fracture risk reduction is less clear for calcium and vitamin D. For calcium, several large, highquality trials could not demonstrate a reduction in fractures among postmenopausal women (39, 72, 73). However, many studies have demonstrated that adherence to calcium treatment is low (39, 72, 73, 88, 89) , and a prespecified analysis in 1 randomized trial demonstrated a reduction in fracture risk among participants who adhered to calcium supplementation (72) .
Across a large body of literature, the effects of vitamin D varied depending on analogue, dose, and fracture type. Among many meta-analyses, some reported a reduced risk for standard vitamin D compared with placebo (25, 27, 33, 36) and some did not (22, 25, 26) . The studies included in the meta-analyses contained some overlap, although each included some unique studies. The findings regarding fracture risk were not related to the size of the pooled sample in the meta-analyses. Notably, 1 metaanalysis reported a reduction in fracture risk for standard vitamin D (D 2 and D 3 ) for doses of 700 to 800 IU/d (27). However, in a large, high-quality trial published after these meta-analyses, 800 IU of vitamin D 3 did not reduce fracture risk compared with placebo among ambulatory patients age 70 years or older with a history of fracture (39). In another trial published after these meta-analyses, 1000 IU of vitamin D reduced hip fracture risk for postmenopausal women with hemiplegia due to stroke (54). For vitamin D analogues (1,25-hydroxyvitamin D and 1-hydroxyvitamin D) compared with placebo, the risk for vertebral fracture was significantly reduced in 3 meta-analyses (25, 33, 36) . For nonvertebral and hip fractures, the evidence was mixed. Together, these data do not prove a universal reduction of fracture risk with vitamin D. However, they do suggest that vitamin D analogues reduce the risk for vertebral fractures and that, in high enough doses, standard vitamin D may prevent fractures in some highrisk populations. The fact that fracture risk reduction was observed among postmenopausal women with hemiplegia suggests that vitamin D might prevent fractures by reducing falls. Indeed, vitamin D-treated patients in the study had a 59% reduction in falls compared with the placebo group, consistent with the vitamin D-associated reduction in falls reported in other studies (161).
Although evidence suggests that many agents reviewed in our report reduce the risk for fracture among postmenopausal women with a high risk for fracture-that is, women with T-scores less than Ϫ2.5 SD or a previous osteoporotic fracture-data on other patient populations are limited. More research is needed to determine whether and which osteoporosis agents reduce fracture risk among transplant recipients. Among lower-risk populations, data are limited on whether osteoporosis agents reduce the risk for fracture among women with osteopenia and among men. Coupled with good evidence that all osteoporosis agents are associated with adverse effects ranging from mild to serious, further research is needed to determine whether the benefits of treatment in these lower-risk populations outweigh the risks. Demonstration of fracture risk reduction could lead to broader use of these agents in these populations and reduced fracture rates; the opposite could lead to discontinuation of these agents in these populations, with a concomitant reduction in associated adverse events and unnecessary health care spending. A practical challenge in determining whether osteoporosis agents reduce the risk for fracture in lower-risk populations is that large sample sizes will be required. Given that the time to develop fractures is longer in lower-risk populations, trials designed to assess fracture risk would require larger sample sizes and longer follow-up than those of typical osteoporosis trials.
Our report also presents the evidence for selected short-and long-term harms (adverse effects) of the various agents. Among cardiac events, an increased risk for serious atrial fibrillation was found in 1 placebo-controlled trial of zoledronic acid (85) . However, this finding was contradicted by the findings of another large trial that was published in the same year (87) . Another placebo-controlled trial suggested a possible increased risk for atrial fibrillation with alendronate (127) . The increased risk for cerebrovascular events reported for estrogen users was also borne out in 3 separate trials (92, 128, 129) .
Among oral bisphosphonate users, the risk for gastrointestinal adverse events has been a concern. The pooled analyses showed a slight increase in esophageal ulcers, as well as mild gastrointestinal events, such as acid reflux. Whereas a pooled analysis of 3 trials also showed a slightly increased risk for more serious adverse events, such as perforations, ulcerations, and bleeding, with etidronate, another pooled analysis showed a decreased risk with daily oral ibandronate. One possible reason for the discrepancy between the apparent risks observed in smaller studies and those of the larger clinical trials is that the larger trials may have enrolled patients who are more likely to adhere to instructions for taking these agents. Alternatively, given the widespread concerns about gastrointestinal side effects, patients enrolled in the large clinical trials may have been given more explicit dosing instructions.
Finally, although we found multiple published cases of osteonecrosis of the jaw in patients with cancer who receive large doses of bisphosphonates intravenously, we could not calculate the risk for this event. A 2006 systematic review (162) identified before preparation of our report analyzed the risk for osteonecrosis of the jaw with bisphosphonate therapy. The researchers found that 94% of published cases were among patients being treated intravenously for cancer. They concluded that although the risk for osteonecrosis of the jaw among patients taking oral bisphosphonates is uncertain, the possible link warrants further investigation (162) . Concerned about the apparently mounting evidence that bisphosphonates increase the risk for osteonecrosis of the jaw, the American Society for Bone and Mineral Research appointed a multidisciplinary task force to address the proposed link. After developing a case definition and reviewing all pertinent literature, the task force concluded in their 2007 report (163) that even though the risk for osteonecrosis of the jaw in patients taking oral bisphosphonates for osteoporosis seemed to be low (in contrast to patients taking the agents intravenously for cancer), the incidence might be higher than that suggested by the literature to date. It outlined an agenda for further research in the area (163) .
The findings reported here should be viewed in the context of the limitations of this study and the research in the field. Although our literature search procedures were extensive and included canvassing experts from academia and industry for studies, other trials may have appeared in non-English-language publications or may have not been published. Publication bias may occur, resulting in an overestimation of the efficacy of these treatments. As for the research itself, many studies of agents to treat osteoporosis measure only changes in bone mineral density and not fracture risk. Most trials that measured fracture risk were inadequately powered to detect even large differences. Most were heterogeneous with respect to study design (criteria for participation, dosing, duration of administration, length of follow-up, or control group), and few considered adherence to the medication regimens. With regard to the assessment of adverse events, the counts of adverse events were limited to those that were explicitly reported in the reviewed studies. Consequently, if many studies failed to report a particular adverse event (because it did not occur in those studies), our analysis would have no way to capture this "nonoccurrence," which could result in our overestimating the risk for that adverse event.
As for our selection of a method to estimate risk differences, both for fracture risk and for the adverse event risk, we chose to use the Peto OR because it has been shown to be the least biased method for estimating rates of rare events, especially compared with the DerSimonian and Laird OR and risk difference methods (164) . The Peto method can be limited if the sample size between the 2 treatment groups is largely imbalanced. As is the case when any OR or risk ratio estimate is being calculated, studies with zero events in the denominator group cannot be calculated by using the Peto OR (12) .
In summary, although good evidence indicates that many agents are effective in preventing osteoporotic fractures, data are insufficient to determine the relative efficacy or safety of these agents. Such studies are unlikely to be performed unless they are required as part of the approval process for these agents. 
